Wingspan Releases its eTMF 2.1 with Integrated Scanning
Wingspan Technology released eTMF 2.1
Wingspan Technology released eTMF 2.1, which builds upon eTMF 2.0, a major update released in April 2014 featuring a commercial-style user interface (UI) and user dashboards. This latest version features integrated scanning capabilities that eliminate the need for manual upload or indexing.
Wingspan eTMF 2.1 provides a streamlined process for high volume scanning of TMF documents by providing printable transmittals that are then attached to documents for scanning. The eTMF uses information from the transmittals to automatically attach metadata to the scanned documents. Once scanned, documents and metadata are released directly into a final Quality Control process.
Read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
